Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab + vinorelbine + cisplatin first-line study in advanced non-squamous non-small cell lung cancer
2007-000971-41Phase 2Completed
- Sponsor
- Grupo Gallego de Cáncer de Pulmón
- Start
- Jan 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, vinorelbine and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Grupo Gallego de Cáncer de Pulmón. Primary endpoint: Progression-free survival. Started Jan 2012; status: completed.
02
Drugs
bevacizumabvinorelbinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-000971-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000971-41.